ProBackend
Neuroscience
3 weeks ago6 min read

Striatal NSF Deletion and Dopamine Loss: What Mouse Research Reveals About ADHD-Like Behavior

Striatal NSF Deletion and Dopamine Loss: What Mouse Research Reveals About ADHD-Like Behavior

A University of Fukui mouse study links NSF deletion in striatal D2 receptor neurons to dopamine loss, ADHD-like behaviors and a response to combination treatment, while highlighting limits for human translation.

NSF deletion in the mouse striatum

Deleting N-ethylmaleimide-sensitive factor (NSF) from dopamine D2 receptor (D2R)-expressing cells in mice was associated with reduced striatal volume, changes in dopamine-related measures, and increased locomotor activity and impulsive behavior. In the study, methylphenidate alone did not significantly suppress hyperactivity, while methylphenidate combined with the D2 receptor agonist quinpirole improved the measured behaviors. It is worth being precise about what that does and does not license: this is one genetically targeted mouse model, and neither NSF disruption as a cause of human ADHD nor the drug combination as a treatment for it has been shown (Neuroscience News).

The study by Min-Jue Xie and colleagues was published in Neuropsychopharmacology on September 15, 2026 (DOI: 10.1038/s41386-026-02526-8). It asks what happens when NSF is removed from D2R-expressing cells during development, and its results give researchers a concrete handle on the link between those cells, striatal development, and dopamine-related behavior. Whether that handle connects to the varied causes and experiences of human ADHD is still an open question.

What the NSF protein actually does

NSF is a membrane-fusion protein involved in intracellular membrane fusion. That process supports neurotransmitter release through synaptic-vesicle docking and recycling, as well as the trafficking of membrane proteins such as receptors. NSF had been shown to interact with the dopamine D2 receptor in cell culture, but what that interaction amounts to in a living brain was not clear.

“Previous findings suggested NSF may be involved in neurodevelopmental and neuropsychiatric disorders. NSF was known to interact with D2R; however, the role of this interaction in vivo remained unclear,” said lead investigator Min-Jue Xie, Ph.D., assistant professor at the University of Fukui’s Research Centre for Child Mental Development. The researchers focused on the interaction in part because striatal dopamine signaling and D2R function have been studied in relation to ADHD (Neuroscience News).

The striatum, a subcortical region involved in motor execution, reward processing, and behavioral control, provided the setting for testing the effects of deleting NSF in D2R-expressing cells.

What happens when NSF is removed from D2R neurons

The researchers engineered conditional knockout mice (Nsf^f/f^;D2R-Cre) lacking NSF in D2R-expressing cells. They reported several developmental and neurochemical differences from control mice:

  • Increased early cell death. The deletion was associated with elevated programmed (apoptotic) cell death during early postnatal development.
  • Changes in D2R-expressing cells and striatal volume. The knockout mice had reduced D2R expression, a lower density of D2R-expressing cells and their associated marker preproenkephalin, and reduced striatal volume.
  • Altered dopamine-related measures. Striatal dopamine concentrations were lower. The researchers also reported reduced dopamine transporter expression in the striatum and reduced tyrosine hydroxylase—an enzyme involved in dopamine synthesis—in the striatum and substantia nigra.

Taken together, these are the fingerprints of a developmental insult to a specific cell population: cells dying early, fewer D2R-expressing cells surviving, a smaller striatum, and a thinner dopamine signal. What remains unproven is that anything like this sequence occurs in people with ADHD (Neuroscience News).

ADHD-like behavior in the knockout mice

The NSF-deficient mice showed elevated locomotor activity and behavior interpreted by the authors as impulsivity. In an elevated-platform impulse-control test, 86% of the knockout mice jumped off within the seven-minute trial, compared with 31% of wild-type control mice (Neuroscience News).

That platform assay is worth a moment's thought, because impulsivity is not a single thing. The jump off a ledge is a decision about restraint, and researchers who study patience and choice generally treat such behavior as involving several distinct computations rather than one deficit. Measuring a mouse's willingness to stay on an elevated platform tells us something about that animal's inhibitory control; it is not a direct equivalent of human ADHD symptoms. The authors suggest that disrupting the NSF–D2R relationship may contribute to ADHD-like behavior in this model, and that is a defensible reading of their data. What it does not show is that NSF loss is a general cause of ADHD in humans: ADHD is heterogeneous, and this model interrogates one particular developmental and dopaminergic pathway.

Stimulant monotherapy failed; the combination worked

In the pharmacological tests, methylphenidate did not significantly suppress hyperactivity in the NSF-deficient mice when given alone. The researchers then tested it with quinpirole, a D2 receptor agonist. The combination improved behavioral regulation in the reported assays; impulsive platform jumping fell from 78% to 11% (Neuroscience News).

The result has an internal logic: if the manipulation degrades D2 receptor function, it is not surprising that a drug acting mainly on dopamine availability, given alone, underperforms, and that adding direct D2 receptor stimulation helps. But the mapping to the clinic is where that logic stops. Quinpirole was used as an experimental agent, and the study does not establish that adding a D2 receptor agonist would benefit patients who do not respond to methylphenidate.

From mouse behavior to human treatment: reading the findings with caution

The study's results are preliminary evidence from basic animal research. Xie described the work as not immediately leading to a new treatment, while noting that it may provide clues about how dopamine-related changes contribute to ADHD-like behavior. The following limitations matter when interpreting the findings:

  • Species and model gaps. Mouse locomotor activity and platform-jumping tests are proxies, not equivalents, for human hyperactivity and impulsivity. Quinpirole is an experimental D2 receptor agonist; this study does not establish its safety or effectiveness as an ADHD treatment in people.
  • A developmental manipulation. NSF was deleted during development, so adult behavior in these mice follows an experimentally induced developmental change. That is not the same as the varied developmental histories of children with ADHD.
  • A targeted cell population. The manipulation concerns NSF in D2R-expressing cells. The findings should not be generalized to other cell populations or interpreted as evidence for NSF effects across other neurotransmitter systems.
  • Human relevance remains untested. The study does not determine whether NSF variation, the NSF–D2R interaction, or D2R-expressing cell measures are associated with ADHD symptoms or treatment response in patients.

What this study adds to ADHD research

The study's real contribution is narrower and more interesting than a headline about an ADHD gene. It takes an NSF–D2R interaction previously observed only in cell culture and shows that, in a living mouse, disrupting it during development is enough to alter striatal structure and dopamine neurochemistry—and that the resulting animals behave in ways the authors map onto ADHD. The drug tests add a second, equally narrow observation: methylphenidate alone did not significantly reduce hyperactivity in these mice, whereas adding quinpirole did, which suggests that stimulant non-response and D2 receptor integrity may interact in at least this model.

Neither observation, however, is a mechanism for human ADHD or a therapeutic recommendation. The useful next steps are concrete: test whether NSF-related measures differ in people with ADHD, check whether the phenotype holds in other D2R-targeted models, and see whether the combination result reproduces before any agonist is considered in a clinical setting. That work is ahead of this paper, and the paper is better for having drawn the line where it did.


Source: Neuroscience News, “Disruption of Striatal D2 Receptor Neurons Drives ADHD and Impulsivity” (September 18, 2026), summarizing Xie M-J, Murata K, Kuniishi H, Fukazawa Y, Usui N, Matsuzaki H. “Deletion of N-ethylmaleimide-sensitive factor in dopamine D2 receptor-expressing cells impairs striatal development and dopaminergic function and induces ADHD-like behaviors in mice,” Neuropsychopharmacology (2026), DOI: 10.1038/s41386-026-02526-8. URL: https://neurosciencenews.com/striatal-d2-receptor-neurons-adhd-31220/. Quantitative and mechanistic details above are drawn from the cited article and the journal abstract it reproduces.

nsf deletion in the mouse striatumnsf deletion in the mouse striatum

nsf deletion in the mouse striatumnsf deletion in the mouse striatum